logo
Share SHARE
FONT-SIZE Plus   Neg

Amgen's AMG 145 Lowers Bad Cholesterol Levels

Amgen Inc. (AMGN) Monday said its experimental drug AMG 145 in combination with statin therapy reduced bad cholesterol levels in patients.

AMG 145 is an investigational antibody directed against PCSK9, a protein that reduces the liver's ability to remove low density lipoprotein cholesterol (LDL-C) or bad cholesterol from the blood.

Amgen in a statement said AMG 145 in combination with statin therapy, with or without ezetimibe, resulted in a reduction in LDL-C by up to 56 percent in patients with heterozygous familial hypercholesterolemia (HeFH) in the Phase 2 Rutherford study.

HeFH, one of the most common genetic disorder, elevates the cholesterol and LDL-C levels and leads to cardiovascular diseases and death.

The company said treatment with AMG 145 every four weeks resulted in a significant LDL-C decrease versus placebo in HeFH patients on lipid-lowering therapy.

At week 12, LDL-C reduction was 43 percent and 55 percent with AMG 145 350 mg and 420 mg, respectively, compared to a 1 percent increase with placebo arm.

"Despite existing therapies and maintaining a healthy lifestyle, patients with heterozygous familial hypercholesterolemia are prematurely at risk for serious cardiovascular disease due to the difficulty in reducing their LDL-C levels," said Frederick Raal, Carbohydrate & Lipid Metabolism Research Unit, Division of Endocrinology & Metabolism, Department of Medicine, University of the Witwatersrand, Johannesburg.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Wal-Mart Stores has disappointed Nintendo fans after it cancelled pre-orders for the Super Nintendo Entertainment System - Classic Edition, a standalone mini Super Nintendo with pre-loaded games. The console is slated to be launched later this fall. Oil company Exxon Mobil Corp. on Friday reported a 97 surge in profit for the second quarter from last year, while Chevron Corp. reported a turnaround to profit in the quarter, both on higher revenues. The results reflect higher crude oil and natural gas prices as well as improved refining margins. However, Exxon Mobil's earnings missed analysts' expectations. Merck (MRK) reported second-quarter Non-GAAP EPS of $1.01 compared to $0.93, a year ago. On average, 16 analysts polled by Thomson Reuters expected the company to report profit per share of $0.87 for the quarter. Analysts' estimates typically exclude special items. Second-quarter net income attributable...
comments powered by Disqus
Follow RTT